je.st
news
Tag: percent
Lexington-based Synta to cut 20 percent of workforce and consolidate lab space
2015-02-06 19:32:24| Biotech - Topix.net
Lexington biotech Synta Pharmaceuticals has announced plans to eliminate 20 percent of its workforce as it slims down to focus on two potential cancer drugs.
Glatfelter to reduce global workforce by 3 percent to 5 percent
2015-02-05 20:34:42| Industrial Machines - Topix.net
Glatfelter said Thursday it plans to shrink its global workforce by 3 percent to 5 percent as weak economic growth in Europe and political uncertainty in Russia and Ukraine affects its business. The York-based paper and fiber manufacturer reported net income of $19.6 million, or 45 cents a share, for the fourth quarter ended Dec. 31. That was up from earnings of $16.5 million, or 37 cents a share, in fourth-quarter 2013.
Tags: to
global
reduce
percent
Daimler Q4 earnings dip 29 percent on anti-trust set-aside
2015-02-05 10:10:29| Automakers - Topix.net
German car and truck maker Daimler AG says net profit fell 29 percent in the fourth quarter as the company set aside 600 million euros for potential costs from a European Union anti-trust investigation of truck makers. Net profit for the October to December quarter fell to 1.187 billion euros from 1.676 billion in the year-earlier quarter.
Tags: percent
earnings
dip
antitrust
Daimler Q4 earnings dip 29 percent on anti-trust set-aside
2015-02-05 10:08:25| Auto Dealers - Topix.net
German car and truck maker Daimler AG says net profit fell 29 percent in the fourth quarter as the company set aside 600 million euros for potential costs from a European Union anti-trust investigation of truck makers. Net profit for the October to December quarter fell to 1.187 billion euros from 1.676 billion in the year-earlier quarter.
Tags: percent
earnings
dip
antitrust
Enanta Announces 95 percent SVR12 Rate In AbbVie's Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients
2015-02-04 07:01:33| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan
Sites : [125] [126] [127] [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] next »